Tysabri and PML: What Does the Safety Data Show?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Specific Risk Assessment

If you or a loved one is taking Tysabri, you may have concerns about the risk of progressive multifocal leukoencephalopathy (PML). Understanding the medical evidence behind this rare but serious side effect is essential for informed decision-making. Drawing on decades of pharmacovigilance research, this page reviews the documented safety profile of Tysabri, including risk stratification, monitoring protocols, and outcomes data.

Find Out If You Qualify for Compensation →

Bridging Clinical Evidence to Occupational Exposure Concerns

From this legacy of health education, we now pivot to the occupational exposure concern. In mass production environments, where workers may encounter biological agents or pharmaceutical residues, understanding the permanence of such adverse outcomes is essential for establishing exposure limits and protective protocols. The same analytical framework used to evaluate patient risk must be adapted to assess workplace safety, ensuring that the lessons from clinical pharmacovigilance inform industrial hygiene practices. Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The prognosis for patients who develop PML from Tysabri is poor, as the condition "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism and Irreversibility of PML from Tysabri

PML is an infection of the brain's white matter that destroys oligodendrocytes, the cells that produce myelin. This damage is typically irreversible, leading to permanent neurological deficits. The FDA label states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). While some patients may survive, the neurological damage is often permanent, resulting in lasting impairments such as cognitive decline, motor dysfunction, vision loss, or speech difficulties. The severity of these deficits depends on the extent of brain involvement and the timeliness of intervention. In clinical trials, PML occurred in three patients: two with multiple sclerosis who had received Tysabri for a median of 120 weeks, and one with Crohn's disease after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases underscore the potential for permanent harm.

Risk Factors and Monitoring for PML

The mechanism linking Tysabri to PML involves its pharmacological action. Tysabri binds to alpha-4 integrins on immune cells, preventing their migration into the brain. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against the JC virus. The virus can then reactivate and cause PML in the brain. Risk factors for developing PML include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy. The prognosis for PML is influenced by the timeline between exposure and harm. PML can occur during Tysabri treatment or after discontinuation. The label notes that "PML has been reported following discontinuation of TYSABRI in patients who did not have findings suggestive of PML at the time of discontinuation" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, monitoring must continue for at least six months after stopping the drug. Early detection is critical: healthcare professionals should monitor patients for any new signs or symptoms suggestive of PML, such as progressive weakness, visual changes, confusion, or personality changes. Tysabri dosing should be withheld immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite early intervention, the damage may still be permanent.

Adequacy of Warnings and Risk Mitigation

The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning and the restricted distribution program. The label includes a boxed warning that clearly states the risk of PML and the need for monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is available only through the TOUCH Prescribing Program, which requires prescribers and patients to be enrolled and to adhere to monitoring protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program aims to mitigate risk but does not eliminate it. The label also recommends obtaining a baseline MRI before starting Tysabri to help differentiate future multiple sclerosis symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For Crohn's disease patients, a baseline MRI may also be helpful, though brain lesions at baseline are uncommon. In summary, PML from Tysabri is often permanent, leading to death or severe disability. The neurological damage is typically irreversible, and survivors may have lasting deficits. The risk is increased by anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. Monitoring for symptoms and withholding Tysabri at the first sign of PML are essential, but even with prompt action, the prognosis remains poor. The warnings and restricted distribution program provide some risk mitigation, but the potential for permanent harm persists.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Is Progressive Multifocal Leukoencephalopathy from Tysabri permanent?

Yes, PML from Tysabri is often permanent. The condition usually leads to death or severe disability, and survivors typically have lasting neurological deficits such as cognitive decline, motor dysfunction, vision loss, or speech difficulties. The damage to the brain's white matter is typically irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be considered when initiating or continuing Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can PML occur after stopping Tysabri?

Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. Therefore, monitoring must continue for at least six months after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.